Publications

Selected publications since 2012. For full list, please visit pubmed.org.

2016

Malátková P., Kanavi M., Nobilis M., Wsol V., 2016. In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 258:153-158. 

Malátková P., Sokolová S., Chocholoušová Havlíková L., Wsól V., 2016. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases. Biochem Pharmacol. 109:83-90.

Hintzpeter J., Seliger J.M., Hofman J., Martin H.J., Wsol V., Maser E, 2016. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance. Toxicol Appl Pharmacol. 293:21-9.

Lundová T., Štambergova H., Zemanová L., Svobodová M., Havránková J., Šafr M., Wsól V., 2016. Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties. Mol Cell Biochem. 411(1-2):35-42. 

Štambergová H., Zemanova L., Lundova T., Malčeková B., Skarka A., Šafr M., Wsol V., 2016. Human DHRS7, promising enzyme in metabolism of steroids and retinoids?. J Steroid Biochem Mol Biol. 155(Pt.A):112-9.

2015

Zemanova L., Hofman J., Novotná E., Musilek K., Lundova T., Havrankova J., Hostalkova A., Chlebek J., Cahlikova L., Wsol V., 2015. Flavones inhibit the activity of AKR1B10, a promising therapetic target for cancer treatment. J Nat Prod. 75(11):2666-74.

Andrys R., Zemanová L., Lenco J., Bilkova Z., Wsol V., 2015. Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier. Chem Biol Interact. 234:169-77. 

Hofman J., Skarka A., Havrankova J., Wsol V., 2015. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochem Pharmacol. 96(3):168-78.  

Lundová T., Zemanová L., Malčeková B., Skarka A., Štambergová H., Havránková J., Šafr M., Wsól V., 2015. Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 234:178-87.  

2014

Hofman J., Malčeková B., Skarka A, Novotná E., Wsol V., 2014. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol. 278(3):238-48. 

Krátký M., Vinšová J., Novotná E., Stolaříková J., 2014. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase. European Journal of Pharmaceutical Sciences, 53:1-9. 

Malátková P., Havlíková L., Wsól V., 2014. The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact., 220C:241-247. 

Malátková P., Wsól V., 2014. Carbonyl reduction pathways in drug metabolism. Drug Metabolism Reviews, 2014, 46(1):96-123. 

Malíř F., Ostrý V., Pfohl-Leszkowicz A., Novotná E., 2014. Ochratoxin A: developmental and reproductive toxicity - an overview. Birth Defects Res B Develop Reprod Toxicol. 98(6):493-502. 

Skarka A., Škarydová L., Štambergová H., Wsól V. Purification and reconstitution of human membrane-bound DHRS7 (SDR34C1) from Sf9 cells. Protein Expression and Purification, 95:44-49. 

Škarydová L., Tomanová R., Havlíková L., Stambergová H., Solich P., Wsól V., 2014. Deeper insight into the reducing biotransformation of bupropion in the human liver. Drug Metab Pharmacokinet., 28(2):177-84. 

Škarydová L., Hofman J., Chlebek J., Havránková J., Kosanová K., Skarka A., Hošťálková A., Plucha T., Cahlíková L., Wsol V., 2014. Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. J Steroid Biochem Mol Biol. 143:250-8. 

Štambergová H., Škarydová Lucie, Dunford, J.E., Wsól, V., 2014. Biochemical properties of human dehydrogenase reductase (SDR family) member 7. Chem-Biological Interact., 207:52-57. 

2013

Skarydova L., Andrys R., Holubova L., Stambergova H., Knavova J., Wsol V., Bilkova Z., 2013. Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand. J Separation Sci, 36(7):1176-84.

Skarydova L., Zverinova M., Stambergova H., Wsol V., 2013. A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK. Drug Metab Lett., 6(3), 174-181. 

Hartmanova T., Tambor V., Lenco J., Staab-Weijnitz C.A., Maser E., Wsól V., 2013. S-Nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity. Chem Biol Interact., 202(1-3):136-145. 

Skarydova L., Nobilis M., Wsól V., 2013. Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica, 43(4):346-354. 

2012

Kozic, J., Novotna, E., Volkova, M., Stolarikova, J., Trejtnar, F., Wsol, V., Vinsova, J., 2012. Synthesis and in vitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2'-hydroxybenzanilides, their thioxo analogues and benzoxazoles. Eur J Med Chem. 56C:108-119.

Kratky, M., Vinsova, J., Novotna, E., Mandikova, J., Wsol, V., Trejtnar, F., Ulmann, V., Stolarikova, J., Fernandes, S., Bhat, S., Liu, J.O., 2012. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis (Edinb) 92:434-439.

Malatkova, P., Ebert, B., Wsol, V., Maser, E., 2012. Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli. Biochem Bbiophysical Res Com., 420, 368-373.

Skarydova, L., Wsol, V., 2012. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. Drug Metab Rev., 44:173-191.

Vesela, R., Aronsson, P., Andersson, M., Wsol, V., Tobin, G., 2012a. The potential of non-adrenergic, non-cholinergic targets in the treatment of interstitial cystitis/painful bladder syndrome. J Physiol Pharmacol., 63:209-216.

Vesela, R., Asklund, H., Aronsson, P., Johnsson, M., Wsol, V., Andersson, M., Tobin, G., 2012b. Coupled nitric oxide and autonomic receptor functional responses in the normal and inflamed urinary bladder of the rat. Phys Res., 61(4):371-80.

© 2017 Charles University, Faculty of Pharmacy in Hradec Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
Website information | Powered by Kentico